Skip to main content

Table 1 Clinicopathological characteristics

From: CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy

Characteristics

No. of patients

Percent

Gender

 Male

215

74.1

 Female

75

25.9

Age

 <65

221

76.2

 ≥ 65

69

23.8

Blood type

 A

101

34.8

 B

73

25.2

 AB

28

9.7

 O

88

30.3

Smoking

 No

128

44.1

 Yes

162

55.9

Drinking

 No

194

66.9

 Yes

96

33.1

Family history

 No

230

79.3

 Yes

60

20.7

Tumor location

 GEJ

8

2.8

 Upper third

32

11.0

 Middle third

54

18.6

 Lower third

172

59.3

 Diffuse

24

8.3

Tumor size (cm)

 < 5

115

39.7

 ≥ 5

175

60.3

ypT

 0

9

3.1

 1–2

57

19.6

 3–4

224

77.3

ypN

 0

100

34.5

 1

49

16.9

 2

79

27.2

 3

62

21.4

ypTNM

 I

52

17.9

 II

71

24.5

 III

167

57.6

Histological type

 Adenocarcinoma

186

64.1

 Poorly cohesive carcinoma

104

35.9

Lauren classification

 Intestinal

143

49.3

 Diffuse or Mixed

147

50.7

Grade of differentiation

 Well

70

25.2

 Moderate or Poor

220

74.8

Vascular or lymphatic invasion

 No

218

75.2

 Yes

72

24.8

Nervous invasion

 

 No

222

76.6

 Yes

68

23.4

Neoadjuvant therapy

 SOX

214

73.8

 XELOX

21

7.2

 FOLFOX

55

19.0

Adjuvant treatment

 No

31

10.7

 Yes

259

89.3

  1. GEJ Gastroesophageal junction